Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphoma, Follicular × spartalizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 7 Melanoma 7 Triple Negative Breast Neoplasms 6 Pancreatic Neoplasms 6 Neoplasms 5 Colorectal Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Lymphoma 4 Liver Neoplasms 4 Lung Neoplasms 3 Esophageal Neoplasms 3 Carcinoma, Hepatocellular 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Sarcoma 2 Multiple Myeloma 2 Locally Advanced Rectal Cancer 2 Kidney Neoplasms 2 Hematologic Diseases 2 Esophageal Squamous Cell Carcinoma 2 Colonic Neoplasms 2 Cholangiocarcinoma 2 Adenocarcinoma 2 Thyroid Carcinoma, Anaplastic 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor, Adult 1 Small Cell Lung Carcinoma 1 Recurrence 1 Rectal Neoplasms 1

Interventions

Rituximab 152 Cyclophosphamide 127 Peripheral Blood Stem Cell Transplantation 66 Filgrastim 57 Etoposide 56 fludarabine phosphate 54 Radiotherapy 48 Vincristine 43 Prednisone 42 Mycophenolic Acid 36 Whole-Body Irradiation 35 Melphalan 33 Doxorubicin 33 Cyclosporine 33 Cytarabine 29 Busulfan 29 Tacrolimus 26 Lenalidomide 26 Carmustine 23 Bendamustine Hydrochloride 23 Methylprednisolone 21 Methotrexate 21 Antilymphocyte Serum 21 Bortezomib 20 Dexamethasone 18 sargramostim 17 ibrutinib 17 ibritumomab tiuxetan 17 fludarabine 17 obinutuzumab 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02677155 2021-03-01

Lymvac-2

Oslo University Hospital

Phase 2 Completed

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡